Published in J Virol on August 19, 2015
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991) 3.78
The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A (2003) 3.34
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature (2007) 3.06
Lassa fever. Curr Top Microbiol Immunol (2002) 3.01
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res (2007) 2.47
Human infection with arenaviruses in the Americas. Curr Top Microbiol Immunol (2002) 2.32
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Treatment of Argentine hemorrhagic fever. Antiviral Res (2007) 1.93
Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology (1994) 1.93
The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol (2004) 1.74
Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A (2009) 1.72
Lymphocytic choriomeningitis virus. A neglected pathogen of man. Arch Pathol Lab Med (1992) 1.71
Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J Virol (2006) 1.71
Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion. J Virol (2006) 1.65
Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology (2006) 1.58
Metabolism and antiviral activity of ribavirin. Virus Res (2005) 1.57
Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis (2001) 1.57
Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am J Obstet Gynecol (2002) 1.50
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol (2008) 1.39
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem (2008) 1.29
X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc Natl Acad Sci U S A (2011) 1.27
Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb Protoc (2012) 1.26
pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol (2008) 1.25
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
Intersubunit interactions modulate pH-induced activation of membrane fusion by the Junin virus envelope glycoprotein GPC. J Virol (2009) 1.15
Cellular entry of lymphocytic choriomeningitis virus. J Virol (2007) 1.12
The entry of Junin virus into Vero cells. Arch Virol (1994) 1.10
The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J Virol (2009) 1.10
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology (2011) 1.10
Lymphocytic choriomeningitis virus: pediatric pathogen and fetal teratogen. Pediatr Infect Dis J (1999) 1.05
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv Virus Res (2002) 0.97
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
The PI3K/Akt pathway contributes to arenavirus budding. J Virol (2012) 0.87
Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J Virol (2013) 0.85
Cell entry of lymphocytic choriomeningitis virus is restricted in myotubes. Virology (2014) 0.78
Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid. Antiviral Res (2013) 0.77
Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol (2015) 0.77
Sodium hydrogen exchangers contribute to arenavirus cell entry. J Virol (2013) 0.82
General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines. J Virol (2015) 0.77
The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses. J Virol (2016) 0.77
Efficient Interaction between Arenavirus Nucleoprotein (NP) and RNA-Dependent RNA Polymerase (L) Is Mediated by the Virus Nucleocapsid (NP-RNA) Template. J Virol (2015) 0.75
Correction for Ngo et al., Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication. J Virol (2016) 0.75